行情

EPZM

EPZM

Epizyme
NASDAQ

实时行情|Nasdaq Last Sale

11.09
+0.03
+0.23%
盘后: 11.09 0 0.00% 16:13 09/23 EDT
开盘
11.03
昨收
11.06
最高
11.40
最低
11.03
成交量
53.21万
成交额
--
52周最高
16.59
52周最低
5.14
市值
10.09亿
市盈率(TTM)
-6.3184
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EPZM 新闻

  • 观点:负利率不会很快来到美国
  • 新浪美股.42分钟前
  • 黄金期货周一收高1.1% 白银跃升4.8%
  • 新浪美股.49分钟前
  • 美联储研究报告称市场对利率降至零的预期上升
  • 新浪美股.1小时前
  • 调查:用户对iPhone11不那么感兴趣 等待明年5G机型
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
-0.69%
制药与医学研究
-0.43%

热门股票

名称
价格
涨跌幅

EPZM 简况

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
展开

Webull提供Epizyme Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。